3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Pancreatic Neoplasms
2
Sarcoma
1
Prostatic Neoplasms
1
Ovarian Neoplasms
1
Melanoma
1
Kidney Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Specimen Handling
6
Magnetic Resonance Spectroscopy
6
Biopsy
6
Doxorubicin
5
pembrolizumab
4
X-Rays
4
Phantoms, Imaging
4
Nuclear Medicine Department, Hospital
4
Cyclophosphamide
4
liposomal doxorubicin
3
fludarabine
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
selpercatinib
2
palbociclib
2
larotrectinib
2
ivosidenib
2
fludarabine phosphate
2
ensartinib
2
atezolizumab
2
anlotinib
2
Temozolomide
2
Radiation
2
Irinotecan
2
Ifosfamide
2
Carboplatin
2
Bevacizumab
2
trifluridine tipiracil drug combination
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Sarcoma
×
Genetic Counseling
×
30 days
×
Clear all
NCT05225428
2026-05-22
VERDI
Dana-Farber Cancer Institute
Phase NA
Recruiting
1,020 enrolled